Health and Healthcare
Genzyme, Buy-Out Target, Makes Mass Layoffs: National Employee Morale Day
Published:
Last Updated:
Genzyme (NASDAQ: GENZ), the target of a buyout offer from Sanofi-Aventis, began to lay-off almost 10% of its workforce today. The company would not say exactly what the size of the cuts would be.
Genzyme may have decided on the move to increase margins. Sanofi-Aventis has offered $18.5 billion to buy the smaller company. Genzyme’s board has dismissed the offer as too low.
Sanofi-Aventis recently disclosed that it has lined-up $10 billion in financial backing to close a transaction.
Lay-offs to increase the value of the company? Cruel.
Douglas A. McIntyre
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.